DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE

« Back to Dashboard

Clinical Trials for Acetazolamide

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000115	Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema	Completed	National Eye Institute (NEI)	Phase 2	To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00004802	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	Ohio State University	Phase 3	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	National Center for Research Resources (NCRR)	Phase 3	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00108602	Sleep Apnea: Mechanism and Cerebrovascular Consequences	Withdrawn	VA Office of Research and Development	N/A	This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.

Clinical Trial Conditions for Acetazolamide

Condition Name

Condition Name for Acetazolamide
Intervention	Trials
Acute Mountain Sickness	7
Altitude Hypoxia	7
Chronic Obstructive Pulmonary Disease	6
Heart Failure	4

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acetazolamide
Intervention	Trials
Altitude Sickness	23
Pulmonary Disease, Chronic Obstructive	10
Lung Diseases	10
Apnea	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acetazolamide

Trials by Country

Trials by Country for Acetazolamide
Location	Trials
United States	82
Kyrgyzstan	16
Canada	6
Israel	6
Switzerland	5

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acetazolamide
Location	Trials
California	7
Massachusetts	6
New York	6
Texas	5
Maryland	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acetazolamide

Clinical Trial Phase

Clinical Trial Phase for Acetazolamide
Clinical Trial Phase	Trials
Phase 4	36
Phase 3	9
Phase 2/Phase 3	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acetazolamide
Clinical Trial Phase	Trials
Recruiting	36
Completed	35
Not yet recruiting	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acetazolamide

Sponsor Name

Sponsor Name for Acetazolamide
Sponsor	Trials
University of Zurich	21
National Center of Cardiology and Internal Medicine, Kyrgyzstan	16
National Eye Institute (NEI)	4

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acetazolamide
Sponsor	Trials
Other	141
NIH	11
U.S. Fed	4

Export unavailable in trial.
Subscribe for complete access.